Phenex Pharmaceuticals AG, founded in 2002, is a privately held Drug Discovery & Development company based in the Biotech Cluster Rhine-Neckar. We are located in the southwest of Germany with labs & offices in Ludwigshafen & Heidelberg.
The company focuses on small-molecule Drug Discovery in disease areas with a huge and unmet medical need. These areas are:
- Liver diseases
- Intestinal diseases
We aim in identifying novel therapeutic principles, i.e. novel molecular mechanisms or targets that provide the basis for the identification of novel drugs with "game changing" capabilities.
Historically, Phenex has identified two of such novel mechanisms from the literature and has translated and developed them into proprietary small molecules as a basis for a novel therapeutic.
The first program, RORγt inverse agonists in inflammation and autoimmune diseases was partnered with Janssen Biotech in a deal valued at 135 M USD in late 2014.
The FXR program, geared towards a drug to treat Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and other severe liver diseases, has been acquired by Gilead Sciences in late 2014 in a 465 M USD deal.
Since both companies, Janssen and Gilead, have progressed our development candidates towards or into the clinic, Phenex can expect further significant milestone payments to come over the next few years.
Phenex invested the proceeds from these deals into novel proprietary drug discovery programs in the three areas Liver diseases, Intestinal diseases and Cancer. The first of these new drug discovery projects have reached a state of maturity which will allow for selecting clinical candidates by late 2016 / early 2017.